Reply to M.C. Chamberlain
- PMID: 24493718
- PMCID: PMC3940542
- DOI: 10.1200/JCO.2013.53.8942
Reply to M.C. Chamberlain
Comment on
-
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).J Clin Oncol. 2013 Sep 1;31(25):3061-8. doi: 10.1200/JCO.2012.46.9957. Epub 2013 Apr 8. J Clin Oncol. 2013. PMID: 23569323 Free PMC article. Clinical Trial.
-
Should dose-intense immunochemotherapy be the new standard of care for primary CNS lymphoma?J Clin Oncol. 2014 Mar 10;32(8):857-8. doi: 10.1200/JCO.2013.53.7084. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493714 No abstract available.
References
-
- Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561–1567. - PubMed
-
- Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol. 2003;21:1044–1049. - PubMed
-
- Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood. 2003;101:466–468. - PubMed
-
- Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25:1350–1356. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
